The safety of biologic therapies in RA-associated interstitial lung disease. - Wikidata - awgldk - TriplyDB

The safety of biologic therapies in RA-associated interstitial lung disease.

The safety of biologic therapies in RA-associated interstitial lung disease.

http://www.wikidata.org/entity/Q38173669

about

Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review The role of biologics in treatment of connective tissue disease-associated interstitial lung disease Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: a case report Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.Adverse reactions to biologic agents and their medical management.Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies.Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease.Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic.Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis.Improvement of the initial stage of interstitial lung disease during psoriasis treatment with secukinumab.Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.

P2860

Q26775753-30A99C9C-E0EF-4C22-90AB-D92CB75D2491 Q28082021-A8A0102E-6C85-4BE9-90B2-F40B06AB60A4 Q35819534-E9168D0C-27B5-435E-809A-7E8257667EE2 Q36270376-1838E2B1-5D30-48B3-ABD9-CF510E0B6205 Q38238948-0212F8FD-DEED-4385-9039-F8F829196CA9 Q38642378-E7B645B1-2EC5-493A-85B3-8CB33257BB21 Q38819214-A3066D8E-1C57-4070-8382-1CE3D1547ED3 Q39100810-37AD5D9A-2628-43F8-8392-3B6C3DAE7791 Q39570333-9D4DA48C-6A71-4699-863E-C05C523955EF Q41687188-BF1FFBAA-17D9-4855-A241-41FADA61DB8B Q45903141-813CF3AC-7A8A-4B7C-B5C5-DA2C3E186D4D Q48097243-9DDE143B-AAF7-496E-BF94-7A7BAEA77D23 Q52983676-4BE82252-0F35-4DF8-8DA6-A9ABD8F5778B

P2860

The safety of biologic therapies in RA-associated interstitial lung disease.

http://www.wikidata.org/entity/Q38173669

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The safety of biologic therapies in RA-associated interstitial lung disease.

@en

type

label

The safety of biologic therapies in RA-associated interstitial lung disease.

@en

prefLabel

The safety of biologic therapies in RA-associated interstitial lung disease.

@en

P1433

Q38173669-1081BD58-31B0-4952-A5AA-DB20AE3FB349

P1476

Q38173669-DBB3E21B-E791-49A8-8EB5-371989DB2656

P2093

Q38173669-7F394FCF-CC81-4A23-8F6D-9A299E47E0F6

Q38173669-9C9830A9-1F34-4276-B037-85665774F283

P2860

Q38173669-0AA69C90-6B6C-4007-9729-94A6AC8CB30C

Q38173669-1A933BCF-E555-4338-B569-A2F493A7598C

Q38173669-1E158ACA-053E-426D-831D-25225FFC52D9

Q38173669-1F178C2E-2B7B-4FB0-81AD-4316C3053D34

Q38173669-225C2E48-7F98-4B7B-A0DF-2E6576306AF7

Q38173669-286E2746-864D-4BFD-BC69-4F7E607EE7CB

Q38173669-29A6E58B-0391-4775-85D3-68464F4EA14C

Q38173669-34A8C6B8-D5E6-4207-AB2F-40C1711DBDC8

Q38173669-370A3094-1938-4B3D-81CC-5F21FB87CA60

Q38173669-46A62E31-4054-4C29-A1C9-CDF2E8D75C1D

P2888

Q38173669-848EA4CB-7C88-4679-AE8A-4EAAF70A8438

P304

Q38173669-8028336B-581A-4C6F-9BDB-4660D16A1872

P31

Q38173669-D6F5121C-F973-45B9-9842-3E5DB22770BF

P356

Q38173669-9ED89A45-58CE-45F0-96D6-CBC45AFC1856

P407

Q38173669-F4D6E701-2845-4C64-BE4D-CF5B29B80307

P433

Q38173669-277AE811-86E1-4228-A0F5-D5F1A57BE39E

P478

Q38173669-8322B69B-B1F0-4C91-A1F5-2BED9DE12FC1

P50

Q38173669-9E586E2F-54F1-490A-8502-8A3075E06CE4

Q38173669-F76D0CC0-2AE0-40FE-80A1-EB29E3F16E0E

P577

Q38173669-660A1B1C-2950-4EA5-A27A-800206577154

P5875

Q38173669-0112E762-2E2F-4F85-BE14-943AD4671A11

P6179

Q38173669-6FC37DA0-0AB6-4EEE-8C5C-FACA3F477382

P698

Q38173669-5C0C7D42-651C-4ECE-AD07-39F8163669E9

P356

NRRHEUM.2013.197

P1433

Nature Reviews Rheumatology

P1476

The safety of biologic therapies in RA-associated interstitial lung disease.

@en

P2093

Eric L Matteson

http://www.w3.org/2001/XMLSchema#string

Nik Hirani

http://www.w3.org/2001/XMLSchema#string

P2860

Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years

Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Non-infectious pulmonary toxicity of rituximab: a systematic review.

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

P2888

nrrheum.2013.197

P304

284-294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRRHEUM.2013.197

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-12-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259456139

http://www.w3.org/2001/XMLSchema#string

P6179

1010146076

http://www.w3.org/2001/XMLSchema#string

P698

24366321

http://www.w3.org/2001/XMLSchema#string